HOME > TOP STORIES

TOP STORIES

ORGANIZATION New Chuikyo Doctor Reps Question Drug Pricing Premiums, CEA Plan

July 19, 2017
BUSINESS Probe Finds No HQ Instruction for Improper Patient Info Acquisition in Xarelto Surveys, Bayer Execs Take 3-Month Pay Cuts

July 18, 2017
REGULATORY Drug Price Cut Only Way to Eke Out FY2018 Funding, though Pharmas Important: Top MD Bureaucrat

July 14, 2017
ACADEMIA JSHR to Conduct 20-Year Follow-Up Study in Up to 100,000 Patients to Determine Efficacy of H. Pylori Eradication Therapy at Preventing Stomach Cancer

July 14, 2017
REGULATORY Chuikyo Starts Debate on Interim Report on CEA, Industry Hearings Slated for Next Meeting

July 13, 2017
REGULATORY MHLW to Announce Data Required for Conditional Early Approval

July 12, 2017
ACADEMIA New Treatment GL for Advanced HCC to Be Issued in October, Will Recommend Nexavar for 1st-Line Treatment

July 11, 2017
BUSINESS Chugai, Osaka Univ. Immunology Collaboration Gets Underway

July 11, 2017
BUSINESS Astellas, Kyoto Univ. Poised to Speed Up Drug Discovery with All-Around Pact

July 10, 2017
BUSINESS RaQualia Aiming for Market Capitalization of 100 Billion Yen by Around 2020: CEO

July 10, 2017
BUSINESS AZ Eyes Japan Durvalumab Launch in NSCLC Maintenance Therapy, Looks to Come from Behind in I/O Race

July 7, 2017
BUSINESS Finishing Line Already in Sight for Govt’s Biosimilar Doubling Goal? Uncertainty Remains with Approval Delays, Discontinuations

July 6, 2017
REGULATORY Chuikyo Reps Trade Barbs over Timing of Post-“CEA” Price Adjustments

July 6, 2017
BUSINESS Delving into Securities Filings - Part 2: Mid-Sized Firms’ Average Pay Dips, 24 Execs Earn Over 100 Million Yen

July 5, 2017
BUSINESS Delving into Securities Filings - Part 1: 27 Drug Makers’ Workforce Down 0.5% as Major Firms Continue to Shed Jobs

July 4, 2017
BUSINESS Ex-JPMA Chief Aoki Wants to See Japan’s Gilead, Govt Leadership in Consolidation

July 3, 2017
REGULATORY MHLW to Soon Present Criteria for Drugs Subject to Optimal Use Guidelines

June 30, 2017
REGULATORY “CEA” Scheme to Be Initially Introduced for Post-Listing Price Adjustment, Targeting Innovative Products with Big Market: Chuikyo

June 29, 2017
REGULATORY Chuikyo Agrees to “Reward Innovation More” when Using Cost Calculation Pricing Method

June 29, 2017
BUSINESS Drug Makers Moving to Outsource “Pharmaceutical Scouting” to Seek Efficiency: Ex-Sanofi Exec

June 28, 2017

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

MHLW Floats Deducting Private-Practice Use for Re-Pricing, but Off-Cycle Cuts Possible; GLP-1 Eyed?

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…